

Product datasheet for TL304800

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

ELAC2 Human shRNA Plasmid Kit (Locus ID 60528)

Product data:

Product Type: shRNA Plasmids

Product Name: ELAC2 Human shRNA Plasmid Kit (Locus ID 60528)

Locus ID: 60528

Synonyms: COXPD17; ELC2; HPC2

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Lentiviral plasmids

Components: ELAC2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 60528).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 001165962, NM 018127, NM 173717, NM 018127.1, NM 018127.2, NM 018127.3,

NM 018127.4, NM 018127.5, NM 018127.6, NM 001165962.1, NM 173717.1, BC004158,

BC004158.2, BC001939, BC046924

UniProt ID: Q9BQ52

Summary: The protein encoded by this gene has a C-terminal domain with tRNA 3′ processing

endoribonuclease activity, which catalyzes the removal of the 3' trailer from precursor tRNAs. The protein also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1), and reduced expression can suppress transforming growth factor-beta induced growth arrest. Mutations in this gene result in an increased risk of prostate cancer. Multiple transcript variants encoding different isoforms

have been found for this gene. [provided by RefSeq, Sep 2009]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).